Article

Eye drops delay onset of glaucoma

Author(s):

Lynda Charters

Bethesda, MD-Glaucoma management has entered a new era. Based on the results of the long-awaited Ocular Hypertension Treatment Study (OHTS), physicians now have clear guidelines for treating patients at high risk for developing glaucoma that may actually prevent the disease.

Related Videos
Related Content
Advanced therapies for retinal vascular diseases
December 23rd 2024

Advanced therapies for retinal vascular diseases

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

4DMT publishes preclinical data demonstrating the potential of the Therapeutic Vector Evolution (TVE) platform
December 20th 2024

4DMT publishes preclinical data demonstrating the potential of the Therapeutic Vector Evolution (TVE) platform

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Study validates long-term efficacy of MicroPulse TLT for glaucoma management
Published: December 19th 2024 | Updated: December 19th 2024

Study validates long-term efficacy of MicroPulse TLT for glaucoma management

Glaucoma 360 offering cutting-edge innovations and networking opportunities
December 19th 2024

Glaucoma 360 offering cutting-edge innovations and networking opportunities

© 2024 MJH Life Sciences

All rights reserved.